MST-0312

MST-0312 (Mestag Therapeutics): sourced facts only. name: "MST-0312 demonstrates potent activation of LTBR in the presence of FAP in human in vitro using patient-derived cancer-associated fibroblasts (CAFs) co-cultured with tumour cell lines." [DOI:10.1158/1538-7445.am2026-lb257]; target: "MST-0312 demonstrates potent activation of LTBR in the presence of FAP in human in vitro using patient-derived cancer-associated fibroblasts (CAFs) co-cultured with tumour cell lines." [DOI:10.1158/1538-7445.am2026-lb257]; target: "MST-0312, a novel FAP-LTBR bispecific antibody, is engineered for tumor-localised LTBR activation, promoting TLS and HEV formation while minimising systemic LTBR activation." [DOI:10.1158/1538-7445.am2026-lb257]; developer: "Mestag Therapeutics Ltd., Cambridge, United Kingdom." [DOI:10.1158/1538-7445.am2026-lb257]; modality: "MST-0312, a novel FAP-LTBR bispecific antibody, is engineered for tumor-localised LTBR activation, promoting TLS and HEV formation while minimising systemic LTBR activation." [DOI:10.1158/1538-7445.am2026-lb257]